LEXAPRO (escitalopram oxalate) by AbbVie is escitalopram, the s-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). Approved for anxiety. First approved in 2002.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
LEXAPRO (escitalopram oxalate) is an oral selective serotonin reuptake inhibitor (SSRI) approved in 2002 for the treatment of anxiety disorders. It works by inhibiting the neuronal reuptake of serotonin (5-HT) in the central nervous system, potentiating serotonergic activity. The drug represents the S-enantiomer of racemic citalopram, offering enhanced pharmacological specificity.
Product approaching loss of exclusivity (May 2026) with moderate competitive pressure (35/100), indicating shrinking team investment and transition focus toward generic stewardship or portfolio repositioning.
escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
Lexapro®'s Efficacy After Dose Escalation in Remission Study
Aripiprazole and Lexapro Drug Interaction Study
Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)
Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro
Worked on LEXAPRO at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on LEXAPRO in 2025 offers limited career growth potential due to imminent LOE and shrinking revenue base, making this a transition or consolidation role rather than a growth opportunity. Professionals should expect team downsizing, focus on generic management, and potential redeployment to higher-priority pipeline assets or AbbVie's emerging anxiety/CNS programs.